Revive Therapeutics Granted FDA Approval For Phase 3 Clinical Trial For Bucillamine In COVID-19 Treatment

It’s a big day for Revive Therapeutics (CSE: RVV) (OTC: RVVTF). The company announced this morning that the US Food and Drug Administration has approved the company’s application for a Phase 3 Clinical Trial for the study of utilizing Bucillamine in the treatment of patients with mild-moderate COVID-19.

The Phase 3 clinical trial will see a randomized, double-blind, placebo-controlled confirmatory study conducted to evaluate the safety and efficacy of Bucillamine in the treatment of the infectious disease. The clinical study, entitled, “A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of Bucillamine in Patients with Mild-Moderate COVID-19,” will see up to 1,000 patients enrolled for testing.

Under the study, patients will be randomized 1:1:1 initially to test the efficacy of two different dosages of Bucillamine in the treatment of COVID-19, with one group being subject to a placebo. Dosages will be administered for a period of up to 14 days, with the objective being to compare frequency of hospitalization or death in patients with mild-moderate COVID-19 among the three groups.

Selkirk Copper Mines — sponsored Sponsored · Selkirk Copper Mines

Efficacy of Bucillamine under the study will be analyzed based on a number of factors, including clinical outcome, disease severity, supplemental oxygen use, and progression of the disease among those whom receive the drug and those of whom receive a placebo.

After 210 patients have been studied for a period of 28 days, the study will then select the better performing dosage of Bucillamine and study it on on 2:1 basis with that of a placebo to further study the efficacy of the drug.

The company intends to execute on the Phase 3 clinical trial in an “expeditious manner.” Full scientific rationale for the use of Bucillamine in the treatment of infectious diseases such as COVID-19 can be found here. 

Revive Therapeutics last traded at $0.24 on the CSE.


FULL DISCLOSURE: Revive Therapeutics is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Revive Therapeutics on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Inside a Forgotten High-Grade Gold Mine in the Yukon | Blue Jay Gold [DD-on-the-GO Ep. 10]

WHICH MINING STOCKS CAN STILL RUN? | Mining Stock Mailbag [Nov. 9-13]

Silver’s Bull Market Isn’t Over | Peter Krauth

Recommended

First Phosphate Adds UK Export Finance to Growing Export Credit Lineup With C$220 Million Letter of Interest

Epic Gold Outlines 150,700 Indicated Ounces at 2.26 G/T in Updated Benoist Resource

Related News

US Weekly Jobless Claims Continue Increasing, Pelosi Proposes Trillions More Dollars In Next COVID Relief Bill

Despite the maximum pressure to get the US through the recovery phase as quickly as...

Saturday, July 11, 2020, 10:30:00 AM

COVID-19 Cases Rise Sharply Across US and Europe as Likelihood of Exponential Spread Grows

As many parts of the US transition towards the cooler climate of fall and winter,...

Monday, October 26, 2020, 03:29:24 PM

Venezuela Experiencing Protests and Looting Amid Food and Fuel Shortages

Although North America is experiencing an oversupply of fossil fuels and bottle-necked food chains amid...

Tuesday, April 28, 2020, 08:40:57 AM

$16 Trillion Price Tag: US Economy Could Lose Nearly its Entire Annual Output Due to Pandemic

The US economy may be heading towards a significantly worse financial situation than previous estimates...

Monday, October 19, 2020, 03:52:18 PM

US Posts Another 4M Jobless Claims; Over 26M in Last 5 Weeks

This morning the Department of Labor announced the initial jobless claimes for the week ended...

Thursday, April 23, 2020, 10:23:46 AM